Status:

RECRUITING

Comparison of Dietetics Support With and Without Continuous Glucose Monitoring in Individuals With Type 2 Diabetes.

Lead Sponsor:

Australian Catholic University

Collaborating Sponsors:

Abbott Diabetes Care

University of Adelaide

Conditions:

Type 2 Diabetes Mellitus (T2DM)

Continuous Glucose Measurement

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

A parallel, single-blinded, randomised clinical trial conducted remotely across Australia from the Mary MacKillop Institute for Health Research (MMIHR, Australian Catholic University) for individuals ...

Detailed Description

In a parallel groups design, a total of 156 individuals will be recruited. After baseline pathology (HbA1c), blinded (Libre Pro iQ) continuous glucose monitoring (CGM) data and questionnaires (via RED...

Eligibility Criteria

Inclusion

  • Aged 18+ years
  • Reside anywhere in Australia and have a postal address
  • Confirmed T2D diagnosis by a GP/endocrinologist
  • Current HbA1c of ≥7.0%
  • Have a smartphone and able to independently use it

Exclusion

  • Under the age of 18 years
  • Use of insulin therapy (within the last three months) or medications which interfere with blood glucose levels (i.e. steroids)
  • Use of CGM within the last six months
  • Eating Disorder Examination Questionnaire (EDE-Q) global score \>2.8 OR global score \> or equal to 1.52, with sum of Q14-18 \> or equal to 4
  • Currently having ongoing consultations with an APD or have had a consult with an APD (within last three months)
  • Not weight stable (\>5 kg change over last three months)
  • Severe hypoglycaemic event (i.e. requiring assistance) within last six months
  • Change of antihyperglcyaemic medications within last three months
  • Women who are pregnant or breastfeeding (within 24 weeks)
  • History of psychotic disorder, or current diagnosis of other major psychiatric illness (e.g. mood disorder, eating disorder, substance use disorder)
  • History of blood disorders (including but, not limited to, anemia and thalassemia) that impact the primary outcome (HbA1c)

Key Trial Info

Start Date :

May 12 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 28 2026

Estimated Enrollment :

156 Patients enrolled

Trial Details

Trial ID

NCT06888687

Start Date

May 12 2025

End Date

November 28 2026

Last Update

May 23 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Australian Catholic University

Melbourne, Victoria, Australia, 3065